6.4.5.1.2.3. nodal-directed therapy rcn1 (with pet/ct). radiolabelled psma pet/ct increasingly used diagnostic tool assess metastatic disease burden patients bcr following prior definitive therapy. review including 30 studies 4,476 patients showed overall estimates positivity restaging setting 38% pelvic lns 13% extra-pelvic ln metastases . percentage positivity psma pet/ct proven increase higher psa values . results review demonstrated high sensitivity specificity 68ga-psma advanced pca, per-lesion-analysed sensitivity specificity 75% 99%, respectively. large retrospective international study included patients ln-recurrent pca (cn1 m1a) psa progression following multi-modality treatment (surgery post-operative rt) . aim study compare standard care (soc) nodal metastasis-directed therapy (mdt). nodal mdt-group showed significantly better css soc control group (5-year survival 98.6% vs. 95.7%, p < 0.01, respectively) . another retrospective study compared sbrt elective nodal irradiation (enrt) nodal oligo-recurrent pca (n = 506 patients, 365 n1 pelvic recurrence). median follow-up 36 months, enrt (n = 197) associated significant reduction nodal recurrences (p < 0.001), compared sabr (n = 309) 2% vs. 18%, respectively. multi-variable analysis, patients one ln recurrence longer adjusted mfs enrt (hr: 0.50, 95% ci: 0.30–0.85, p = 0.009). tendency relapse higher pelvic- extra-pelvic nodes (p < 0.001) . patients presenting two (extra)pelvic lns, adjusted mfs significantly different (hr: 0.92, 95% ci: 0.54– 1.59, p = 0.8). situations, sabr used highly selected patients prospective cohorts clinical trials only, recommendations made. mdt m1 patients see section 6.4.7.